Hypertension With High-Risk Features in Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized - Scorecard - MDSpire

Hypertension With High-Risk Features in Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized

  • By

  • Mohamed Ridha

  • Raed Hailat

  • Robert Stanton

  • Alexander E. Merkler

  • Mitchell S. V. Elkind

  • W. T. Longstreth

  • David L. Tirschwell

  • Richard A. Kronmal

  • Yousef Hannawi

  • Hooman Kamel

  • James Burke

  • Daniel Woo

  • June 1, 2026

  • 0 min

Share

Clinical Scorecard: Exploring High-Risk Hypertension Characteristics in Cryptogenic Stroke: Insights from the ARCADIA Randomized Study

At a Glance

CategoryDetail
Condition
Key MechanismsAnticoagulation vs antiplatelet therapy in embolic stroke of undetermined source.
Target Population
Care Setting

Key Highlights

    Guideline-Based Recommendations

    Diagnosis

      Management

      • Patients were randomized to apixaban or aspirin for secondary prevention.

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients with cryptogenic stroke and atrial cardiopathy.

          Apixaban administered as 5 mg twice daily, with dose reduction criteria.

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Hypertension With High-Risk Features in Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized

            • by Mohamed Ridha, Raed Hailat, Robert Stanton, Alexander E. Merkler, Mitchell S. V. Elkind, W. T. Longstreth, David L. Tirschwell, Richard A. Kronmal, Yousef Hannawi, Hooman Kamel, James Burke, Daniel Woo

            • June 1, 2026

            Related Content

            Effects of remote transitional care on stroke patients: a meta-analysis

            Zinc homeostasis dysregulation in elderly patients with acute ischemic stroke: a multidimensional analysis integrating metallothionein, FADS1 activity, oxidative stress, and DNA integrity markers

            Efficacy observation of electromyography-guided targeted injection of swallowing muscles for treating dysphagia resulting from medullary paralysis